Taipei, Taiwan, (December 12, 2025) – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472) announced that it has received a series of sustainability recognitions this quarter across corporate governance and decarbonization. The company was honored with the Taiwan Corporate Sustainability Awards (TCSA) – Corporate Sustainability Excellence Award, the Silver Award in the Corporate Sustainability Report Award , and was named among Taiwan’s leading business and financial publication Business Weekly’s “2025 Top 100 Carbon Competitiveness Leaders.”
Chairman Bobby Sheng underscored the Company’s commitment to advancing sustainability, noting that Bora’s decarbonization strategy, transparent disclosures, and strengthened governance practices are beginning to show meaningful progress. “Beyond Taiwan’s marquee awards, we have also achieved year-over-year improvements in globally recognized third-party sustainability assessments such as EcoVadis and FTSE Russell – benchmarks closely watched by global pharmaceutical clients,” he said. “These advancements reflect years of disciplined, systemized management and cross-functional alignment. They also affirm the way we link our sustainability strategy to operational efficiency metrics and to the compensation structure of our senior leadership team.”
Recap on Bora’s performance across multiple domestic and international sustainability and corporate governance assessments:
- EcoVadis: Score of 52 at the “Committed” level, exceeding the 45-point threshold commonly required by many of the world’s top 50 pharmaceutical companies.
- FTSE Russell ESG Score: 3.5 out of 5, meeting the inclusion criteria of the FTSE4Good Index Series.
- TWSE Corporate Governance Evaluation: Ranked in the top 6%–20% and included as a constituent of TWSE Corporate Governance 100 Index and Fubon Corporate Governance ETF (00692).
- MSCI ESG Rating: Rated “A”, reflecting strong performance in ESG risk management and resilience.
Looking ahead, Bora will continue to place sustainability at the core of its operations and apply a “lead-and-lift” approach to cascade best practices across all sites within the Group. This model, where mature (in ESG management) sites help accelerate the capabilities of newer ones, has enabled Bora to integrate all environmental data from its U.S. facilities within a year of their acquisition. In Canada, 5 years after joining the Group, the site has independently established its own sustainability committee and launched its SBTi-aligned decarbonization roadmap, becoming a flagship decarbonization site that the Group is proud of. Bora plans to launch a similarly structured program for the social pillar in 2026, bringing its pharma sales operations into the Group’s sustainability cycle to further amplify the company’s mission-driven role in improving health all over the world.